Duravyu gained 2.5 letters vs 6.1 with aflibercept at week 52/56, missing noninferiority in a second phase 3 wet AMD trial.
Commentary|Articles|September 8, 2026
Beyond anti-VEGF: A multi-mechanism TKI approach to DME
Author(s)Kassi Filkins, Dante Pieramici, MD
Dante Pieramici, MD, discusses the phase 3 COMO and CAPRI trials of EYP-1901 in diabetic macular edema and what 6-month dosing could mean for treatment burden.
Advertisement
Advertisement
Extended-release drug delivery is reshaping the treatment landscape for retinal vascular disease, offering a potential answer to the persistent gap between the efficacy of anti-VEGF therapy in clinical trials and the undertreatment many patients experience in the real world.
Related to this article
OT Roundup covers the optogenetics Nobel Prize, remigromig in DME with Veeral Sheth, MD, Stargardt disease and a total human eye transplant.
Eclipse Life Sciences reports that its biodegradable 6-month fluocinolone acetonide implant met its primary safety end point and beat the dexamethasone implant on visual and anatomic measures at 24 weeks.
Ehsan Rahimy, MD, says most PRIMA serious adverse events occurred early, while vision gains held through 36 months.
Jacque Duncan, MD, reviews phase 3 DRAGON data on oral tinlarebant for Stargardt disease and its mechanism-related visual effects.
Jordi Monés, MD, PhD, explains why RP and Stargardt data support testing son-vec to restore vision in advanced GA.
Two phase 1 OSPREY cohorts of intravitreal STK-002 for ADOA are dosed; first safety and efficacy data are expected by mid-2027.
A higher risk of central serous chorioretinopathy and serous pigment epithelial detachment are associated with varicose veins.
Advertisement
Advertisement